Companies Profiled : The report provides profiles of the companies in the global anti-obesity prescription drugs market such as , F Hoffmann La Roche Ltd , Orexigen Therapeutics , Inc , Novo Nordisk A / S , Arena Pharmaceuticals , Inc , GlaxoSmithKline , VIVUS , Inc , Boehringer Ingelheim , Alizyme and Others . Recently approved Saxenda by Novo Nordisk is growing at a fast growth rate due to rising interest among obese people . Novo Nordisk , an innovator of drugs in the obesity market , introduces Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 ( GLP-1 ) receptor agonist , liraglutide , This Dual therapy can be used for both obesity and type 2 diabetes is the latest trend in the market . Click the Below Full Report Link https :// www . infiniumglobalresearch . com / healthcare _ medical _ devices / global _ antiobesity _ prescription _ drugs _ market
Report Highlights : The report provides deep insights on demand forecasts , market trends and micro and macro indicators . In addition , this report provides insights on the factors that are driving and restraining the global anti-obesity prescription drugs market . Moreover , IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider . The report provides insights into the market using analytical tools such as Porter ' s five forces analysis and DRO analysis of anti-obesity prescription drugs market . Moreover , the study highlights current market trends and provides forecast from 2018-2024 . We also have highlighted future trends in the anti-obesity prescription drugs market that will impact the demand during the forecast period . Moreover , the competitive analysis given in each regional market brings an insight on the market share of the leading players . This report will help manufacturers , suppliers and distributors of the antiobesity prescription drugs market to understand the present and future trends in this market and formulate their strategies accordingly .
Infinium Global Research